Should I Buy KROS? KROS 2026 Analysis

Should You Buy Keros Therapeutics Inc (KROS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

17.570

1 Day change

1.91%

52 Week Range

22.550

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (for an impatient entry): trend/positioning skew bearish and there’s no proprietary “strong buy” trigger.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Price is sitting just above near-term support (~17.80); without a catalyst, upside looks limited versus the risk of a breakdown.
Options positioning (put-heavy open interest + very high IV) implies the market is pricing elevated downside/tail risk into the near term.
No recent news catalyst, with the next clear event being earnings (2026-02-26 AH), which can keep traders cautious.

Technical Analysis

Trend/Momentum: MACD histogram is below zero (-0.0648) and still negative (bearish), though the negative momentum is contracting (selling pressure may be easing, not reversing).
RSI (6): 38.77 — weak/soft momentum, approaching oversold but not a clear reversal signal.
Moving averages: converging MAs suggest consolidation after a decline; not yet a confirmed uptrend.
Key levels:
- Support: S1 17.801 (then S2 17.261)
- Pivot: 18.676 (needs reclaim for improved near-term tone)
- Resistance: R1 19.551 (then R2 20.091)
Tactical read: A bounce is possible if 17.80 holds, but the setup is not strong enough to justify an “impatient buy” without confirmation above ~18.68/19.55.

Options Data

Bearish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put-call ratio at 2.41 is notably put-heavy (bearish/hedged stance).
Volatility: 30D implied volatility 125.15 vs historical volatility 45.14; IV percentile 94.42 = options are pricing unusually large moves (market sees event/tail risk).
Flow: Today’s volume is tiny (4 contracts), but volume vs 30D average is 7.55x and open interest is elevated vs average (52.19x), suggesting positioning is already built and sensitivity to catalysts is high.
Net take: Options market is not signaling an easy long right now; it’s priced for big movement with put-skewed protection.

Technical Summary

Sell

Buy

Positive Catalysts

- Pipeline optimism from analysts: continued durability/safety read-through for KER-065, and expectation of Phase 2 initiation for DMD in Q1 2026 (per Oppenheimer).
- Potential technical bounce if 17.80 support holds and price reclaims 18.68 pivot.
- Upcoming QDEC 2025 earnings on 2026-02-26 (after hours) can act as a catalyst if guidance/updates surprise positively.

Neutral/Negative Catalysts

- Bearish options skew (put-heavy open interest) plus very high IV suggests the market is braced for downside or adverse surprises.
- No news in the last week: lack of fresh catalysts can keep the stock pinned/weak into earnings.
- Risk-off tape: pre-market S&P 500 -0.64% adds pressure to small-cap biotech sentiment.
- Event risk into earnings (2026-02-26 AH) may deter aggressive buyers ahead of the print.

Financial Performance

Latest reported quarter: 2025/Q3
Revenue: 14.262M, +3575.77% YoY (sharp increase, likely milestone/partner-driven rather than steady product revenue).
Profitability: Net income -7.28M (worse YoY, -86.25%); EPS -0.18 (down -87.23% YoY) — losses widened.
Gross margin: 100% (typical for certain biotech revenue types; doesn’t offset operating loss trend).
Bottom line: top-line spike is encouraging, but earnings trend remains negative and doesn’t yet support a “buy now without confirmation” stance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent direction: price targets have been raised, but ratings are mixed.
Oppenheimer (Outperform): raised PT to $27 from $23 (2025-11-07 / 2025-11-12), citing encouraging KER-065 data and Phase 2 timing expectations.
BofA (Neutral): raised PT to $19 from $18 (2025-11-28) after Q3 updates.
Wall Street pros: differentiated mechanism/early safety-durability signals; upcoming clinical milestones.
Wall Street cons: still loss-making with biotech execution risk; near-term market positioning looks defensive (consistent with cautious stance into catalysts).
Influential/political trading: no recent congress trading data available; hedge funds and insiders noted as Neutral (no significant recent trend).

7 Analyst Rating

Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 21.2 USD with a low forecast of 16 USD and a high forecast of 27 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

Current: 17.240

Low

Averages

21.2

High

Current: 17.240

Low

Averages

21.2

High

BofA

Jason Zemansky

Neutral

maintain

$18 -> $19

AI Analysis

2025-11-28

Reason

BofA

Jason Zemansky

Price Target

$18 -> $19

AI Analysis

2025-11-28

maintain

Neutral

Reason

BofA analyst Jason Zemansky raised the firm's price target on Keros Therapeutics to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the company's Q3 earnings update.

Oppenheimer

Andreas Argyrides

Outperform

maintain

$23 -> $27

2025-11-12

Reason

Oppenheimer

Andreas Argyrides

Price Target

$23 -> $27

2025-11-12

maintain

Outperform

Reason

Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business update. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and sees broader potential across other bone disorders.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KROS

Unlock Now

KROS Should I Buy

KROS Should I Buy

Should You Buy Keros Therapeutics Inc (KROS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch